CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%- clindamycin 1% / niacinamide 2% / tazarotene 0.05% gel 
Sincerus Florida, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05%

Directions for use

d

Sincerus Florida, LLC. Adverse reactions

zz

Active, inactive

s

NDC 72934-1050-2 CLINDAMYCIN PHOSPHATE USP 1% / NIACINAMIDE USP 2% / TAZAROTENE 0.05%. Gel 30gm

d

CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05% 
clindamycin 1% / niacinamide 2% / tazarotene 0.05% gel
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72934-1050
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
TAZAROTENE (UNII: 81BDR9Y8PS) (TAZAROTENE - UNII:81BDR9Y8PS) TAZAROTENE0.05 g  in 100 g
NIACINAMIDE (UNII: 25X51I8RD4) (NIACINAMIDE - UNII:25X51I8RD4) NIACINAMIDE2 g  in 100 g
CLINDAMYCIN PHOSPHATE (UNII: EH6D7113I8) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN PHOSPHATE1 g  in 100 g
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:72934-1050-230 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product05/10/2019
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other05/10/2019
Labeler - Sincerus Florida, LLC (080105003)
Establishment
NameAddressID/FEIBusiness Operations
Sincerus Florida, LLC080105003manufacture(72934-1050)

Revised: 5/2019
Document Id: 8878edb5-6d17-5633-e053-2995a90a1486
Set id: 8878edb5-6d16-5633-e053-2995a90a1486
Version: 1
Effective Time: 20190509
 
Sincerus Florida, LLC